Safety and efficacy evaluation of albumin-bound paclitaxel

Bibliography

• Wani MC, Taylor HL, Wall ME, et al. Plant antitumoragents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7
   PubMed Web of Science ®Google Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53
   PubMed Web of Science ®Google Scholar
• Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998;5:827-35
   PubMed Web of Science ®Google Scholar
• Herve F, Urien S, Albengres E, et al. Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 1994;26:44-58
   PubMed Web of Science ®Google Scholar
• Henderson C, Bhatia V. Neb-paclitaxel for breast cancer: a new formulation with an improved safety profile and grater efficacy. Expert Rev Anticancer Ther 2007;7:919-43
   PubMed Web of Science ®Google Scholar
• Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-27
   PubMed Web of Science ®Google Scholar
• Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J Cell Biol 2008;182:623-9
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59-64
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-0079) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43
   PubMed Web of Science ®Google Scholar
• Cancer facts and figures. American Cancer Society. 2012. Available from: www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf [Last Accessed 12 December 2013]
   Google Scholar
• Surveillance, epidemiology and end results. SEER stat fact sheets: breast. National Cancer Institute. 2012. Available from: http://seer.cancer.gov/statfacts/html/breast.html [Last Accessed 2 December 2013]
   Google Scholar
• O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10(Suppl 3):20-9
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• Conory T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• von Hoff DD, Thomas E, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs. gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2012;30(Suppl 34):abstract LBA148
   Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;17:2055-62
   Google Scholar
• Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909
   PubMed Web of Science ®Google Scholar
• Seidman A, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004;23:A512
   Google Scholar
• Chirgwin J, Chua SL. Management of breast cancer with nanoparticle albumin-bound (nab) paclitaxel combination regimens: a clinical review. Breast 2011;20:394-406
   PubMed Web of Science ®Google Scholar
• Seidman AD, Conlin AK, Bach A, et al. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 2013;13:239-46
   PubMed Web of Science ®Google Scholar
• Danso MA, Blum JL, Robert NJ, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer [abstract 1075]. USA: 44th Annual Meeting of the American Society of Clinical Oncology; Chicago; 2008
   Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nabpaclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer 2012;12:313-21
   PubMed Web of Science ®Google Scholar
• Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-72
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat 2013;138:829-37
   PubMed Web of Science ®Google Scholar
• Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase I trial. Int J Radiat Oncol Biol Phys 2002;54:137-41
   PubMed Web of Science ®Google Scholar
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2012;31:23-9
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-18
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42
   PubMed Web of Science ®Google Scholar
• Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26
   PubMed Web of Science ®Google Scholar
• Mirtsching B, Cosgriff T, Harker G, et al. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer 2011;11:121-8
   PubMed Web of Science ®Google Scholar
• Link JS, Waisman JR, Nguyen B, Jacobs CI. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 2007;7:779-83
   PubMed Web of Science ®Google Scholar
• Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010;10:281-7
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Arena FP, Mintzer DM, et al. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer 2012;12:87-93
   PubMed Web of Science ®Google Scholar
• Roy V, LaPlant BR, Gross GG, et al. North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53
   PubMed Web of Science ®Google Scholar
• Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:427-35
   PubMed Web of Science ®Google Scholar
• Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer 2013;13:416-20
   PubMed Web of Science ®Google Scholar
• Yardley DA, Hart L, Bosserman L, et al. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat 2013;137:457-64
   PubMed Web of Science ®Google Scholar